Marketdash
Back to News

Four Stocks Get the Downgrade Treatment: Biogen Analyst Shifts to Bearish

MarketDash Editorial Team
3 hours ago
Wall Street analysts turned more cautious on four stocks Wednesday, with Biogen facing a rare downgrade to "Reduce" and three other companies seeing their ratings cut to neutral territory. Here's what prompted the shift in sentiment.

It wasn't a great day for four companies on Wall Street's watch list, as prominent analysts across multiple firms decided to pump the brakes on their recommendations. The downgrades span sectors from biotech to industrial apparel, showing that analyst caution is spreading broadly.

Leading the bearish moves, HSBC analyst Rajesh Kumar took Biogen Inc. (BIIB) from Hold to Reduce—essentially a sell recommendation—while trimming the price target from $144 to $143. The downgrade is notable given that Biogen shares closed at $175.84 on Tuesday, suggesting Kumar sees significant downside ahead for the biotech company.

Meanwhile, Guggenheim analyst Howard Ma pulled back his enthusiasm for Confluent, Inc. (CFLT), downgrading the data streaming platform from Buy to Neutral. Confluent shares finished Tuesday's session at $29.90, apparently no longer offering the upside potential that previously justified a buy rating.

In the industrial space, DA Davidson analyst Michael Shlisky delivered a double dose of bad news to Lakeland Industries, Inc. (LAKE), downgrading the protective clothing manufacturer from Buy to Neutral while slashing the price target from $20 to $14. That's a 30% haircut to the target, bringing it closer to Tuesday's closing price of $15.01.

Rounding out the downgrades, Jefferies analyst Saree Boroditsky moved Veralto Corporation (VLTO) from Buy to Hold and lowered the price target substantially from $125 to $105. With Veralto shares closing at $98.41 on Tuesday, the new target suggests limited upside from current levels.

These rating changes reflect shifting analyst perspectives on growth prospects, valuation concerns, or changing industry dynamics. For investors holding these stocks, the downgrades serve as a reminder to reassess thesis and risk tolerance, especially when multiple analysts start turning more cautious on their positions.

Back to News

Four Stocks Get the Downgrade Treatment: Biogen Analyst Shifts to Bearish

MarketDash Editorial Team
3 hours ago
Wall Street analysts turned more cautious on four stocks Wednesday, with Biogen facing a rare downgrade to "Reduce" and three other companies seeing their ratings cut to neutral territory. Here's what prompted the shift in sentiment.

It wasn't a great day for four companies on Wall Street's watch list, as prominent analysts across multiple firms decided to pump the brakes on their recommendations. The downgrades span sectors from biotech to industrial apparel, showing that analyst caution is spreading broadly.

Leading the bearish moves, HSBC analyst Rajesh Kumar took Biogen Inc. (BIIB) from Hold to Reduce—essentially a sell recommendation—while trimming the price target from $144 to $143. The downgrade is notable given that Biogen shares closed at $175.84 on Tuesday, suggesting Kumar sees significant downside ahead for the biotech company.

Meanwhile, Guggenheim analyst Howard Ma pulled back his enthusiasm for Confluent, Inc. (CFLT), downgrading the data streaming platform from Buy to Neutral. Confluent shares finished Tuesday's session at $29.90, apparently no longer offering the upside potential that previously justified a buy rating.

In the industrial space, DA Davidson analyst Michael Shlisky delivered a double dose of bad news to Lakeland Industries, Inc. (LAKE), downgrading the protective clothing manufacturer from Buy to Neutral while slashing the price target from $20 to $14. That's a 30% haircut to the target, bringing it closer to Tuesday's closing price of $15.01.

Rounding out the downgrades, Jefferies analyst Saree Boroditsky moved Veralto Corporation (VLTO) from Buy to Hold and lowered the price target substantially from $125 to $105. With Veralto shares closing at $98.41 on Tuesday, the new target suggests limited upside from current levels.

These rating changes reflect shifting analyst perspectives on growth prospects, valuation concerns, or changing industry dynamics. For investors holding these stocks, the downgrades serve as a reminder to reassess thesis and risk tolerance, especially when multiple analysts start turning more cautious on their positions.